NCT03983239View on ClinicalTrials.gov

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

November 2, 2019

Study Completion Date

November 6, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

Fedratinib

Fedratinib

DRUG

Rifampin

Rifampin

DRUG

Efavirenz

Efavirenz

Trial Locations (1)

75247

Covance Clinical Research Unit Inc - Dallas, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

INDUSTRY

lead

Celgene

INDUSTRY